Castle Biosciences to Present at Upcoming Investor Conferences

Rhea-AI Summary

Castle Biosciences (Nasdaq: CSTL) announced that CEO Derek Maetzold will present at two investor conferences. The first is the BTIG Virtual MedTech Conference on Feb. 17, 2021, at 10:30 a.m. ET, followed by the 10th Annual SVB Leerink Global Healthcare Conference on Feb. 24, 2021, at 10:00 a.m. ET. Live webcasts of the presentations will be available on Castle's website, with replays accessible for two weeks afterward. Castle focuses on providing personalized genomic information to enhance treatment decisions for skin cancer.

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the following upcoming investor conferences:

• BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Feb. 17, 2021, at 10:30 a.m. Eastern time.

• 10th Annual SVB Leerink Global Healthcare Conference on Feb. 24, 2021, at 10:00 a.m. Eastern time.

Live audio webcasts of the company’s presentations will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/news-events/events-presentations. Replays of the webcasts will be available for two weeks following the conclusion of the live broadcasts.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx^®-Melanoma, DecisionDx^®-CMSeq), cutaneous squamous cell carcinoma (DecisionDx^®-SCC), suspicious pigmented lesions (DecisionDx^® DiffDx™-Melanoma) and uveal melanoma (DecisionDx^®-UM, DecisionDx^®-PRAME and DecisionDx^®-UMSeq). For more information about Castle’s gene expression profile tests, visit www.CastleTestInfo.com. Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit www.CastleBiosciences.com.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq and are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005035/en/

FAQ

When is Castle Biosciences' presentation at the BTIG Conference?

Castle Biosciences' presentation at the BTIG Virtual MedTech Conference is scheduled for February 17, 2021, at 10:30 a.m. Eastern time.

What is the date of the SVB Leerink Global Healthcare Conference presentation by CSTL?

The 10th Annual SVB Leerink Global Healthcare Conference presentation by Castle Biosciences (CSTL) is on February 24, 2021, at 10:00 a.m. Eastern time.

Where can I watch the Castle Biosciences conference presentations?

Live audio webcasts of Castle Biosciences' conference presentations can be accessed on their website, with replays available for two weeks after.

What does Castle Biosciences specialize in?

Castle Biosciences specializes in providing personalized genomic information for improving treatment decisions in skin cancer.